|
1
|
Ferlay J, Soerjomataram I, Ervik M, Forman
D, Bray F, Dikshit R, Elser S, Mathers C, Rebelo M and Parkin DM:
GLOBOCAN 2012 v10, Lung Cancer Estimated Incidence, Mortality and
Prevalence Worldwide in 2012. International Agency for Research on
Cancer. World Health Organization; Lyon: 2013, http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
Accessed July 7, 2017.
|
|
2
|
Pfister DG, Johnson DH, Azzoli CG, Sause
W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT,
et al American Society of Clinical Oncology: American Society of
Clinical Oncology treatment of unresectable non-small-cell lung
cancer guideline: Update 2003. J Clin Oncol. 22:330–353. 2004.
View Article : Google Scholar
|
|
3
|
Howlader N, Noone A, Krapcho M, Miller D,
Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, et
al: SEER Cancer Statistics Review, 1975–2013. National Cancer
Institute; Bethesda, MD: 2017, https://seer.cancer.gov/archive/csr/1975_2013/.
Accessed July 7, 2017.
|
|
4
|
Sorenson CM: Bcl-2 family members and
disease. Biochim Biophys Acta. 1644:169–177. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liam CK, Pang YK, Leow CH, Poosparajah S
and Menon A: Changes in the distribution of lung cancer cell types
and patient demography in a developing multiracial Asian country:
Experience of a university teaching hospital. Lung Cancer.
53:23–30. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Soini Y, Kinnula V, Kaarteenaho-Wiik R,
Kurttila E, Linnainmaa K and Pääkkö P: Apoptosis and expression of
apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in
malignant mesothelioma. Clin Cancer Res. 5:3508–3515.
1999.PubMed/NCBI
|
|
7
|
Othman N, In LL, Harikrishna JA and Hasima
N: Bcl-xL silencing induces alterations in hsa-miR-608 expression
and subsequent cell death in A549 and SK-LU1 human lung
adeno-carcinoma cells. PLoS One. 8:e817352013. View Article : Google Scholar
|
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hayashita Y, Osada H, Tatematsu Y, Yamada
H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y and
Takahashi T: A polycistronic microRNA cluster, miR-17-92, is
overexpressed in human lung cancers and enhances cell
proliferation. Cancer Res. 65:9628–9632. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shivdasani RA: MicroRNAs: Regulators of
gene expression and cell differentiation. Blood. 108:3646–3653.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Phuah NH, Azmi MN, Awang K and Nagoor NH:
Downregulation of microRNA-210 confers sensitivity towards
1′S-1′-acetoxychavicol acetate (ACA) in cervical cancer cells by
targeting SMAD4. Mol Cells. 40:291–298. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mott JL, Kobayashi S, Bronk SF and Gores
GJ: mir-29 regulates Mcl-1 protein expression and apoptosis.
Oncogene. 26:6133–6140. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Othman N and Nagoor NH: The role of
microRNAs in the regulation of apoptosis in lung cancer and its
application in cancer treatment. BioMed Res Int. 2014:3180302014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Koo KH and Kwon H: MicroRNA miR-4779
suppresses tumor growth by inducing apoptosis and cell cycle arrest
through direct targeting of PAK2 and CCND3. Cell Death Dis.
9:77–91. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yuan L, Li S, Zhou Q, Wang D, Zou D, Shu J
and Huang Y: miR-124 inhibits invasion and induces apoptosis of
ovarian cancer cells by targeting programmed cell death 6. Oncol
Lett. 14:7311–7317. 2017.
|
|
16
|
Lv KT, Liu Z, Feng J, Zhao W, Hao T, Ding
WY, Chu JP and Gao LJ: miR-22-3p regulates cell proliferation and
inhibits cell apoptosis through targeting the eIF4EBP3 gene in
human cervical squamous carcinoma cells. Int J Med Sci. 15:142–152.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gang L, Qun L, Liu WD, Li YS, Xu YZ and
Yuan DT: MicroRNA-34a promotes cell cycle arrest and apoptosis and
suppresses cell adhesion by targeting DUSP1 in osteosarcoma. Am J
Transl Res. 9:5388–5399. 2017.
|
|
18
|
Grimson A, Farh KK, Johnston WK,
Garrett-Engele P, Lim LP and Bartel DP: MicroRNA targeting
specificity in mammals: Determinants beyond seed pairing. Mol Cell.
27:91–105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar
|
|
20
|
Yang J, Song K, Krebs TL, Jackson MW and
Danielpour D: Rb/E2F4 and Smad2/3 link survivin to TGF-beta-induced
apoptosis and tumor progression. Oncogene. 27:5326–5338. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jang CW, Chen CH, Chen CC, Chen JY, Su YH
and Chen RH: TGF-beta induces apoptosis through Smad-mediated
expression of DAP-kinase. Nat Cell Biol. 4:51–58. 2002. View Article : Google Scholar
|
|
22
|
Van Themsche C, Chaudhry P, Leblanc V,
Parent S and Asselin E: XIAP gene expression and function is
regulated by autocrine and paracrine TGF-beta signaling. Mol
Cancer. 9:216–228. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Leech SH, Olie RA, Gautschi O, Simões-Wüst
AP, Tschopp S, Häner R, Hall J, Stahel RA and Zangemeister-Wittke
U: Induction of apoptosis in lung-cancer cells following bcl-xL
anti-sense treatment. Int J Cancer. 86:570–576. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ma F, Song H, Guo B, Zhang Y, Zheng Y, Lin
C, Wu Y, Guan G, Sha R, Zhou Q, et al: miR-361-5p inhibits
colorectal and gastric cancer growth and metastasis by targeting
staphylococcal nuclease domain containing-1. Oncotarget.
6:17404–17416. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu D, Tao T, Xu B, Chen S, Liu C, Zhang
L, Lu K, Huang Y, Jiang L, Zhang X, et al: miR-361-5p acts as a
tumor suppressor in prostate cancer by targeting signal transducer
and activator of transcription-6 (STAT6). Biochem Biophys Res
Commun. 445:151–156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun JJ, Chen GY and Xie ZT:
MicroRNA-361-5p inhibits cancer cell growth by targeting CXCR6 in
hepatocellular carcinoma. Cell Physiol Biochem. 38:777–785. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cao ZG, Huang YN, Yao L, Liu YR, Hu X, Hou
YF and Shao ZM: Positive expression of miR-361-5p indicates better
prognosis for breast cancer patients. J Thorac Dis. 8:1772–1779.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu X, Xi X, Yan Q, Zhang Z, Cai B, Lu W
and Wan X: MicroRNA-361-5p facilitates cervical cancer progression
through mediation of epithelial-to-mesenchymal transition. Med
Oncol. 30:751–762. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Derynck R, Zhang Y and Feng XH: Smads:
Transcriptional activators of TGF-beta responses. Cell. 95:737–740.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Itoh S, Itoh F, Goumans MJ and Ten Dijke
P: Signaling of transforming growth factor-beta family members
through Smad proteins. Eur J Biochem. 267:6954–6967. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Massagué J: How cells read TGF-beta
signals. Nat Rev Mol Cell Biol. 1:169–178. 2000. View Article : Google Scholar
|
|
32
|
Massagué J and Wotton D: Transcriptional
control by the TGF-beta/Smad signaling system. EMBO J.
19:1745–1754. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Miyazono K: TGF-beta signaling by Smad
proteins. Cytokine Growth Factor Rev. 11:15–22. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hoot KE, Lighthall J, Han G, Lu SL, Li A,
Ju W, Kulesz-Martin M, Bottinger E and Wang XJ:
Keratinocyte-specific Smad2 ablation results in increased
epithelial-mesenchymal transition during skin cancer formation and
progression. J Clin Invest. 118:2722–2732. 2008.PubMed/NCBI
|
|
35
|
Munker S, Weng HL, Li Q, Liu Y, Meyer C,
Dooley S and Li J: Differential Smad expression contributes to
severity of cholangiocarcinoma. Z Gastroenterol. 50:K1022012.
View Article : Google Scholar
|
|
36
|
Wu Y, Li Q, Zhou X, Yu J, Mu Y, Munker S,
Xu C, Shen Z, Müllenbach R, Liu Y, et al: Decreased levels of
active SMAD2 correlate with poor prognosis in gastric cancer. PLoS
One. 7:e356842012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Samanta D and Datta PK: Alterations in the
Smad pathway in human cancers. Front Biosci. 17:1281–1293. 2012.
View Article : Google Scholar
|
|
38
|
Yang J, Wahdan-Alaswad R and Danielpour D:
Critical role of Smad2 in tumor suppression and transforming growth
factor-beta-induced apoptosis of prostate epithelial cells. Cancer
Res. 69:2185–2190. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang H, Jiang JY, Zhu C, Peng C and Tsang
BK: Role and regulation of nodal/activin receptor-like kinase 7
signaling pathway in the control of ovarian follicular atresia. Mol
Endocrinol. 20:2469–2482. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu G, Zhou H, Wang Q, Auersperg N and Peng
C: Activin receptor-like kinase 7 induces apoptosis through
up-regulation of Bax and down-regulation of Xiap in normal and
malignant ovarian epithelial cell lines. Mol Cancer Res. 4:235–246.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xu F, Zhou D, Meng X, Wang X, Liu C, Huang
C, Li J and Zhang L: Smad2 increases the apoptosis of activated
human hepatic stellate cells induced by TRAIL. Int Immunopharmacol.
32:76–86. 2016. View Article : Google Scholar : PubMed/NCBI
|
